AIMS:To evaluate the real-world effectiveness of combination therapy with glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose co-transporter 2 inhibitors (SGLT2-I) on glucose control in type 2 diabetes (T2D) and to identify clinical predictors of treatment response. METHODS:We retrospectively analyzed data from 549 subjects with T2D treated with combined GLP-1RA and SGLT2-I therapy. Clinical and biochemical parameters were collected at baseline and after 6-9 months of follow-up. Therapy response was defined according to drug-specific expected glycated hemoglobin (HbA1C) reduction thresholds, based on the known efficacy of each innovative molecule. Logistic regression and receiver operating characteristic analyses were used to identify predictors of response. Decision curve analysis was performed to assess the utility of predictive models. RESULTS:41.9% of subjects achieved the expected HbA1C reduction. Baseline HbA1C was the strongest predictor of response (odds ratio: 6.60 per 1% [≈11 mmol/mol] increase). Follow-up reductions in fasting plasma glucose and body mass index, and increases in high-density lipoprotein cholesterol, were also associated with response. Decision curve analysis demonstrated that both baseline and extended models provided higher net benefit than treat-all and treat-none strategies. CONCLUSIONS:Combination therapy with GLP-1RA and SGLT2-I improves glucose control in a substantial proportion of subjects with T2D. Integrating baseline glycaemic burden with longitudinal metabolic changes may support individualized clinical decision-making.

Background/Objectives: Diabetic retinopathy (DR) is a major microvascular complication of type 2 diabetes (T2D) and a leading cause of visual impairment. While traditional risk factors contribute to DR development, the role of dietary habits and their association with vision-related quality of life remains unclear. This study investigated the relationship between dietary intake, DR, and vision-related quality of life in subjects with T2D. Methods: In this cross-sectional study, 129 subjects with T2D were classified as no DR (NDR; n = 85), non-proliferative DR (NPDR; n = 36), or proliferative DR (PDR; n = 8). Dietary intake was assessed using a food frequency questionnaire, Mediterranean diet (MD) adherence by the MD Score, and vision-related quality of life by the NEI-VFQ-25. Multivariable logistic regression identified factors associated with DR. Results: DR was present in 34.1% of participants. Subjects with DR had longer diabetes duration than those without DR (18 vs. 16 years, p < 0.01), with 12% higher odds of DR per additional year. Overall MD adherence did not differ between groups; however, lower legume consumption was independently associated with higher odds of DR (OR 2.5, 95% CI 1.1–5.8, p = 0.037). PDR was associated with poorer vision-related quality of life. Higher saturated fat intake correlated with worse questionnaire scores, whereas monounsaturated fatty acids and vitamin E showed positive associations. Conclusions: Specific dietary components, rather than overall MD adherence, were associated with DR and vision-related quality of life, supporting targeted nutritional strategies in DR management.

Background/Objectives: Diabetic retinopathy (DR) is a major microvascular complication of type 2 diabetes (T2D) and a leading cause of visual impairment. The relationships among Mediterranean diet adherence, dietary components, DR, and vision-related quality of life remain incompletely defined. This cross-sectional study evaluated Mediterranean Diet Score (MDS) as the primary dietary endpoint, individual MDS components as secondary endpoints, and micronutrient intakes as exploratory endpoints. Methods: In this single-centre study, 129 subjects with long-standing T2D were classified as no DR (NDR; n = 85), non-proliferative DR (NPDR; n = 36), or proliferative DR (PDR; n = 8). Dietary intake was assessed using a food frequency questionnaire and vision-related quality of life using the NEI-VFQ-25. Results: Subjects with DR had longer diabetes duration than those without DR (18 vs. 16 years, p < 0.01). Overall MDS did not differ by DR status, indicating a null finding for the primary dietary endpoint. In secondary analyses, lower legume consumption was observed among participants with DR and was associated with higher odds of DR in multivariable models. Participants with PDR showed poorer vision-related quality of life, although this finding was limited by the small PDR subgroup and high NEI-VFQ-25 scores in other groups. Exploratory analyses suggested associations between selected micronutrient intakes and NEI-VFQ-25 domains. Conclusions: Overall Mediterranean diet adherence was not associated with DR status. Secondary and exploratory findings should be considered hypothesis-generating and require confirmation in prospective studies.

Unannounced meals pose a major challenge to type 1 diabetes patients. This study compared the performance of two automated insulin delivery (AID) algorithms, the Medtronic MiniMed 780G’s proportional-integral-derivative (PID) and the Tandem t: slim X2’s model predictive control (MPC), following unannounced breakfasts (ClinicalTrials.gov identifier: NCT07455643, retrospectively registered the 3rd of February 2026). In a randomized crossover study, we enrolled 20 children between 11 and 18 years using the MiniMed 780G or the Tandem t: slim X2 AID system. Endpoints included 2-hour and 4-hour blood glucose difference (ΔBG), glucose peak, time to peak, and time spent above (TAR), below (TBS), in range (TIR), and in tight range (TITR). Two meals were tested: a carbohydrate (CHO) meal and a mixed one, both containing 30 g of carbohydrates, and additional 15 g proteins for the mixed meal. Announced (AM) and unannounced (UM) meals were analyzed. AM, compared to UM, showed significant higher 2-hourΔBG; conversely 4-hourΔBG did not differ significantly. In CHO AM, algorithms were comparable. In mixed AM, PID gained lower peaks and TAR, with higher TIR and TITR. In UM, PID obtained lower 2-hourΔBG than MPC, with reduced peak, TAR, and improved TIR and TITR. Differences in 4-hourΔBG and time-at-peak were not significant. Both AID algorithms mitigated postprandial glycemia and returned glucose to baseline levels within 4 h without safety concerns. The PID demonstrated higher reactivity to unannounced meals, while performances were comparable when meal boluses were properly announced. NCT07455643.

INTRODUCTION:Sarcopenia is the progressive skeletal muscle impairment that affects 10-16 % of the elderly worldwide. Sarcopenia can be recognised at any age, particularly in subjects with a wide range of conditions, including metabolic diseases. We conducted a systematic review of current evidence on the association between sarcopenia and type 1 diabetes (T1D). METHODS:We searched in PubMed-Medline and Web of Science databases. PRISMA guidelines were applied, and the risk of bias was assessed following the RoB 2.0 and ROBINS-I V2 tools. RESULTS:A total of 15 studies were included. Most of the studies were published in the last five years (n = 13), were undertaken in Europe (n = 7) or Asia (n = 6), had a cross-sectional design (n = 13), and enrolled adult T1D subjects (n = 12). The sample size of the included studies varied from 16 to 177 T1D subjects. CONCLUSION:Sarcopenia represents a relevant issue in T1D subjects in all age groups. Older age and lower BMI are the main determinants of muscle decline, while conflicting data are available on diabetes duration, glucose control, dietary and physical exercise behaviours. Despite these initial findings, future research should clarify the molecular basis of muscle impairment in T1D and establish accurate diagnostic procedures, preventive and therapeutic trajectories.

Background/Objectives: Nutrition during the reproductive years shapes women’s immediate health, fertility, pregnancy outcomes, and long-term offspring well-being. This position paper narratively synthesizes and critically appraises evidence on how dietary patterns, macro-/micronutrients, and supplementation influence women’s health, female fertility, and reproductive outcomes, to inform practical recommendations. Methods: We narratively reviewed recent reviews, cohort studies, clinical trials, and public-health guidance on macronutrients, key micronutrients, dietary patterns (with emphasis on the Mediterranean diet), ultra-processed food (UPF) intake, and targeted supplementation relevant to menstrual, metabolic, cardiovascular, skeletal, and reproductive outcomes. Results: Balanced, diverse diets rich in whole and minimally processed foods support hormonal regulation, ovulatory function, healthy gestation, and chronic-disease risk reduction. Priority nutrients include iron, folate, calcium, vitamin D, zinc, vitamin B12, and long-chain omega-3s (DHA), with supplementation considered when dietary intake or bioavailability is inadequate. Evidence consistently links Mediterranean-style eating to improved metabolic health, insulin sensitivity, IVF success, lower gestational diabetes risk, and favorable neonatal outcomes. High UPF consumption is associated with poorer diet quality, inflammation, adverse pregnancy outcomes, and potential reproductive impairment, warranting a reduction in favor of nutrient-dense foods. Diet also influences cardiovascular and bone health through effects on lipids, glycemia, blood pressure, and mineral/vitamin status, with fiber-rich carbohydrates, unsaturated fats (notably olive oil), and adequate calcium–vitamin D emerging as central levers. Conclusions: For women of childbearing age, a Mediterranean-aligned, minimally processed dietary pattern—tailored to individual needs and complemented by prudent use of folate, iron, vitamin D, calcium, B12, and DHA when indicated—offers robust benefits across reproductive, metabolic, cardiovascular, and skeletal domains. Public-health actions should improve access to healthy foods, curb UPF marketing, and embed personalized nutrition counseling in routine care; further longitudinal research from preconception through postpartum is needed.

Diabetes and cancer are two of the most common public health concerns worldwide. The complex interplay of these two conditions is a growing area of research, as patients with diabetes are at increased risk for developing cancer, and vice versa. Furthermore, both patient populations show increased risk of many communicable infectious diseases and their adverse consequences, while vaccination can play a crucial role in their prevention, improving patient outcomes. Vaccination should represent a standard part of care for patients with cancer, diabetes, and both the diseases simultaneously, including people undergoing cancer treatment or in remission. Several international guidelines provide recommendations for vaccinating people with cancer or diabetes, but the two conditions have not been specifically evaluated together. Here we present a multidisciplinary consensus position paper on vaccination in patients with cancer and diabetes. The position paper is the result of a collaborative effort between experts from the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), and Italian Society of Pharmacology (SIF). The paper provides a comprehensive overview of the current state-of-the-art knowledge on vaccination in patients with cancer and diabetes. It discusses the importance of vaccination in preventing infections, focuses attention on the need to consider the unique challenges faced by patients with cancer and diabetes when it comes to vaccine administration, and highlights the need for coordinated care to optimize treatment outcomes. Overall, the consensus position paper provides healthcare professionals caring for patients with cancer and diabetes recommendations on the use of various vaccines, including influenza, COVID-19, HZV, and HPV vaccines, as well as guidance on how to address common concerns and challenges related to vaccine administration.

PURPOSE:This position statement addressed the limited scientific literature on the management of diabetes mellitus secondary to endocrinopathies, despite its frequent occurrence in hormonal diseases such as acromegaly, Cushing's syndrome, primary hyperaldosteronism, pheochromocytoma, hyperthyroidism, and neuroendocrine tumors. The aim was to review the pathophysiological mechanisms, clinical features, and management strategies, focusing on nutritional and pharmacological approaches. METHODS:A comprehensive review of existing literature was conducted regarding studies on diabetes secondary to endocrinopathies and the effects of treatments for these conditions, such as somatostatin analogues and pancreatic surgery. Particular emphasis was placed on understanding glucose metabolism derangements and the interplay between endocrine excess and therapeutic interventions. RESULTS:Secondary diabetes arises not only from hormone excess but also as a consequence of treatments for endocrine disorders. For instance, somatostatin analogues, while effective in resolving hormone hypersecretion, impair glucose metabolism by inhibiting pancreatic insulin secretion. Similarly, pancreatic surgery for neuroendocrine tumors often exacerbates glycemic disturbances. The management of secondary diabetes requires a multidisciplinary approach that includes treating the underlying endocrine disorder, tailoring antidiabetic therapy, and optimizing nutritional strategies to mitigate metabolic disruptions. CONCLUSION:Diabetes secondary to endocrinopathies presents unique challenges due to its complex etiology and the metabolic effects of treatments. This position statement underscores the importance of an integrated management approach, offering guidance for clinicians in addressing this multifaceted condition. Further research is needed to develop evidence-based guidelines for optimal care.

Cancer survivors have been considered individuals who have completed anti-tumor treatment and are in “remission”. However, the definition is increasingly seen as insufficient due to a significant number of patients living with chronic or stable disease, as a result of advanced therapies, and according to a recent definition, “survivors” are all people living with and beyond cancer. Breast, prostate, lung and colorectal cancers are the most frequent tumors diagnosed in Europe with an increasing population of survivors. The longer life expectancy has made it necessary to assess the health status, comorbidities, and complications in cancer patients, mainly in the age range of 20–50 years. In particular, the long-lasting hormonal therapies in hormone-sensitive tumors and the immunotherapies, that are changing the cancer clinical scenario, have opened a broad landscape of late endocrine/metabolic toxicities. The aim of the present manuscript is to evaluate the late endocrine-metabolic complications in survivors of young adult or adult-onset cancers in the most prevalent tumors, analyzing risk factors for endocrine/metabolic disease, attempting to provide a indications for long-term surveillance and treatment strategies. This paper highlights the importance of recognizing endocrine and metabolic complications, as well as identifying key risk factors that can suggest a more effective surveillance and management.

OBJECTIVE:This study aimed to correlate the parameters of advanced hybrid closed loop (AHCL) function to the glycometabolic outcomes in a cohort of patients with type 1 diabetes (T1D) using different AHCL systems. RESEARCH DESIGN AND METHODS:This was a retrospective cross-sectional study on 124 adult (n = 87) and pediatric (n = 37) patients correlating the total daily insulin dose (TDD), the total daily basal (TDBa) and bolus (TDBo) insulin doses, the percentage of auto-bolus out of total daily bolus (Automated Correction Index - ACI) to the glycated hemoglobin (HbA1c) and the sensor-derived metrics. RESULTS:The ACI was the only AHCL-derived parameter directly associated to HbA1c (p = 0.03) and time above range (TAR180-250 mg/dL, 10-13.9 mmol/L, p < 0.01), and inversely correlated to time in range (TIR70-180 mg/dL, 3.9-10 mmol/L, p < 0.01). Patients with ACI < 30 % showed reduced HbA1c levels (6.21 % ± 0.5 vs. 6.95 % ± 0.8, p = 0.02) and a higher probability of having TIR > 70 % (OR 3.18, CI 1.19-8.46, p = 0.02) and coefficient of variation (CV) < 36 % (OR 2.86, CI 1.07-8.27, p = 0.03) compared to those with ACI ≥ 30 %. CONCLUSION:The ACI could represent a useful and easy-to-assess metric for AHCL-treated individuals with T1D. In our cohort an ACI < 30 % was associated to better glucose control and variability.

The insulin receptor (IR) is a tetrameric, tyrosine-kinase receptor, composed of two α-subunits and two transmembrane β-subunits. Alternative splicing of exon 11 generates two structurally different isoforms: IR-A and IR-B. The 12 amino acids derived from exon 11 are included in the IR-B isoform but not in the IR-A isoform. IR-A predominates in tissues with more active proliferation, it is manly expressed in embryonal and fetal tissues, central nervous system (CNS), hematopoietic cells and cancer cells. IR-B is predominantly expressed in adult, well-differentiated tissues, it mediates metabolic insulin actions in liver, muscle and fat. The mechanisms that regulate IR isoform expression are complex and not fully understood. The most relevant functional difference between these two isoforms is the high affinity of IR-A for Insulin-like Growth Factor II (IGF-II), whereas IR-B has a low affinity for IGF-II. In murine embryonal fibroblasts deprived of Insulin-like Growth Factor I receptor (IGF-IR), IGF-II is able to stimulate cell proliferation through the IR-A isoform. Studies in different breast cancer cells demonstrate that IR-A, the high affinity receptor for IGF-II, promotes cell proliferation. In addition, in various sarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via IR-A. These data are confirmed in patients with osteosarcoma, who show elevated serum IGF-II, associated with survival reduction. Both stromal and epithelial cancer cells can locally produce IGF-II, thus suggesting that an autocrine/paracrine IGF-II/IR-A loop promotes cancer cell proliferation. In agreement with differential roles of insulin receptor isoforms described above, mature human osteoblasts mainly express IR-B, whereas IR-A is more expressed in osteoblast precursors. Accordingly, insulin receptor isoforms A and B stimulate different intracellular signaling pathways. When activated by insulin, the IR-B mainly generates metabolic effects, whereas the IR-A, activated by insulin or IGF-II, mediates mitogenic effects.

Proper nutrition is essential during pregnancy to ensure an adequate supply of nutrients to the foetus and adequate maternal weight gain. In pregnancy complicated by diabetes (both gestational and pre-gestational), diet in terms of both the intake and quality of carbohydrates is an essential factor in glycaemic control. Maternal BMI at conception defines the correct weight increase during gestation in order to reduce maternal-foetal complications related to hypo- or hyper-nutrition. The recommendations presented here, which are based on national and international guidelines and the most recently published data on nutrition in physiological pregnancy and pregnancy complicated by hyperglycaemia and/or obesity, are designed to help healthcare professionals prescribe suitable eating patterns to safeguard the health of the mother and the foetus.

Background/Objectives: Over the past decade, numerous studies have explored the bidirectional relationship between obesity and mental health, mainly eating disorders (EDs). This study aimed to assess the prevalence and characteristics of altered eating behaviors (AEBs) in a cohort of people with obesity (PwO) using the validated Eating Behaviors Assessment for Obesity (EBA-O). Methods: We conducted a cross-sectional study from May 2023 to April 2024, recruiting consecutive PwO seeking weight loss. Participants completed the 18-item EBA-O questionnaire, which focuses on five primary eating behaviors: night eating, food addiction, sweet eating, hyperphagia, and binge eating. Unlike other validated tools, the EBA-O is specifically designed to capture these behaviors in PwO and is easy for patients to self-administer. We also collected sociodemographic and clinical data. Results: A total of 127 participants were included (76 women, median age 52 years, median BMI 42.9 kg/m2). We found a significant prevalence of AEBs: 33.1% for sweet eating, 23.6% for hyperphagia, 15.7% for food addiction, 14.2% for binge eating, and 7.1% for night eating. The EBA-O scores correlated positively with BMI (r = 0.201, p = 0.024) and increased across BMI categories (p = 0.001). Males had higher scores for night eating and hyperphagia (p = 0.01), and active smokers had higher hyperphagia scores (p = 0.043) than ex-smokers and non-smokers. The night eating scores were inversely correlated with sleep hours (r = -0.197, p = 0.026), and food addiction was positively correlated with age (r = 0.261, p = 0.003); conversely, hyperphagia (r = -0.198, p = 0.025) and binge eating (r = -0.229, p = 0.010) were inversely correlated with age. PwO without diabetes had higher scores for food addiction (p = 0.01) and binge eating (p = 0.004) compared to those with diabetes. Conclusions: These results highlight the potential to characterize PwO based on their AEBs, offering new opportunities to tailor treatment strategies for PwO by targeting specific eating behaviors.

The worldwide growing prevalence of diabetes and cancer led to an increase in subjects affected by both these diseases that share several of the involved risk factors and have a complex, multifactorial etiopathogenesis. Cancer therapies could have harmful effects on several organs, particularly in subjects also affected by diabetes and its related comorbidities. Moreover, cancer diagnosis often monopolizes the attention of both patients and caregivers, thus reducing the attention to pre-existent diseases. Retinopathy is one of the most frequent microvascular complications of diabetes, accounting for about 5% of legal blindness worldwide. The retinal neurovascular unit is dysfunctional in diabetes and could represent a frail site when cancer therapies are administered. Nevertheless, the short- and long-term effects of the different anticancer molecules on retinal tissue, especially in diabetic subjects, are poorly known, and no specific recommendations on their prevention and management are available. In this review, we summarised the current data on this topic, focusing on the different cancer class drugs involved in retinal damage: anti-oestrogen, classical cytolytic chemotherapy (alkylating agents, taxanes, topoisomerase inhibitors, and antimetabolites), mitogen-activated protein kinase, tyrosine-kinase, and vascular endothelial growth factor inhibitors are the cancer drugs associated with retinal damage and visual disturbance. However, further studies are necessary to improve knowledge on the molecular and clinical relation between cancer therapies and retinopathy, in order to provide clinicians with evidence-based protocols to optimise the management of these conditions and minimise vision loss occurrence, impaired quality of life, and public health expense.

Background: Increasing evidence suggests that diabetes increases the risk of developing different types of cancer. Hyperinsulinemia, hyperglycemia and chronic inflammation, characteristic of diabetes, could represent possible mechanisms involved in cancer development in diabetic patients. At the same time, cancer increases the risk of developing new-onset diabetes, mainly caused by the use of specific anticancer therapies. Of note, diabetes has been associated with a ∼10% increase in mortality for all cancers in comparison with subjects who did not have diabetes. Diabetes is associated with a worse prognosis in patients with cancer, and more recent findings suggest a key role for poor glycemic control in this regard. Nevertheless, the association between glycemic control and cancer outcomes in oncologic patients with diabetes remains unsettled and poorly debated. Purpose: The current review seeks to summarize the available evidence on the effect of glycemic control on cancer outcomes, as well as on the possibility that timely treatment of hyperglycemia and improved glycemic control in patients with cancer and diabetes may favorably affect cancer outcomes.

Aim Recently, the relationship between diabetes and mental health has been widely studied. With the advent of continuous glucose monitoring (CGM), some researchers have been interested in exploring the association between glucose-related metrics and psychological aspects. These studies have primarily relied on self-report questionnaires which present some limitations. Therefore, the present multicenter study aims at testing potential associations between CGM metrics and affective processes derived from narratives about using a CGM sensor. Methods An exploratory correlational design was used. Fifty-eight adults with type 1 diabetes using CGM were enrolled and invited to complete an online survey, where they replied to an open-ended question regarding their personal experience with the CGM sensor. Texts derived from the answers were analyzed through Linguistic Inquiry and Word Count, a widely used text analysis tool that can automatically identify and quantify linguistic patterns related to various psychological dimensions. Psycholinguistic measures were correlated with CGM metrics. Results Higher levels of sadness/depression correlated with lower %TIR ( r = − 339; p < .01) and higher %TAR ( r = .342; p < .01). Conclusions The study highlights the relationship between CGM metrics and psychological variables derived from patients' narratives. In particular, it is possible to hypothesize a positive role of %TIR in reducing depressive feelings in individuals with diabetes, as well as a negative role of depressive feelings in achieving desirable CGM outcomes. Additionally, there is a potential role of glycemic variability, particularly hyperglycemia, in the expression of depressive and sad feelings, which has been less studied compared to the effects of hypoglycemia.

Aim: To assess the effectiveness of a phone reminder to improve adherence to post-partum glucose tolerance testing in women with gestational diabetes mellitus (GDM) and to identify clinical predictors of adherence to post-partum follow-up. Methods: Retrospective study including 543 women with GDM. We assessed the adherence rate to post-partum glucose tolerance testing in women who received a phone reminder (n = 297) compared to women not alerted (n = 246). Demographic and clinical variables were collected to identify the predictors of adherence to the post-partum oral glucose tolerance test (OGTT). Results: The adherence to post-partum OGTT was higher in women who received the phone reminder compared to those not alerted (60.6 % vs. 35.4 %, p < 0.001). Women less compliant compared to those more compliant, had a higher pre-pregnancy body mass index (BMI) (29.3 +/- 7.9 vs. 27.0 +/- 6.1 Kg/m2, p = 0.03). The adherence was lower in pre-pregnant obese compared to non-obese women (42.7 % vs. 52.0 %, p < 0.05), in women with only one, compared to multiple OGTT alterations during pregnancy (44.5 % vs. 57.8 %, p < 0.05), and in women non-insulin treated compared to those insulin-treated (40.0 % vs. 57.1 % vs, p < 0.001). Conclusions: The phone reminder improved post-partum follow-up adherence. Pre-pregnancy BMI, number of OGTT alterations and type of therapy could identify poorly adherent women.

BACKGROUND: In cancer patients with diabetes, anticancer drugs (ADs) may negatively affect the course of diabetes vascular complications. The short-term effects of ADs on type 2 diabetes (T2D) retinopathy are poorly known. This study evaluated the short-term effects of different classes of ADs on diabetic retinopathy (DR) and clinical risk factors for retinal worsening (RW) in cancer patients affected by T2D.METHODS: Retrospective single-centre study evaluating 168 patients with T2D and cancer. The diagnosis of T2D preceded those of cancer in all patients. We evaluated the retinal short-term effects within the six months after the first-line ADs treatment.RESULTS: After ADs, 6% of patients had a short-term RW. BMI is positively associated with the risk of RW (OR 1.45, 95% confidence interval (CI) 1.1-1.9, p<0.005). Patients treated with alkylating agents and topoisomerase inhibitors have an increased risk of RW (p=0.049 and p=0.057, respectively) and a significantly higher HDL level (p<0.01).CONCLUSIONS: To our knowledge, this study is the first investigating the short-term impact of ADs on DR of T2D patients. Moreover, we provide information arose from a real-world setting. As confirmed by other studies, these findings could help to identify patients at risk for shortterm RW, who should be promptly referred to the ophthalmologist for the prevention of visual impairment.

Immunotherapy with immune checkpoint inhibitors (ICI) is increasingly employed in oncology. National and international endocrine and oncologic scientific societies have provided guidelines for the management of endocrine immune-related adverse events. However, guidelines recommendations differ according to the specific filed, particularly pertaining to recommendations for the timing of endocrine testing. In this position paper, a panel of experts of the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), and Italian Society of Pharmacology (SIF) offers a critical multidisciplinary consensus for a clear, simple, useful, and easily applicable endocrine-metabolic assessment checklist for cancer patients on immunotherapy.